MTA3

Across TCGA pan-cancer cohorts, MTA3 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated MTA3 data layer compared with 2 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MTA3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTA3 expression acts as an unfavorable survival marker, although some lineages such as LGG and THYM show a favorable association.

LIHC, ACC, and KIRP are the cancer types where MTA3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Quartile	All	0.641	0.868	<.001	86	view →
ACC	DFS	Median	II,III,IV	0.218	0.645	<.001	84	view →
KIRP	OS	Quartile	All	0.736	0.929	<.001	37	view →
LGG	DFS	Median	All	0.874	0.788	<.001	32	view →
BLCA	DFS	Median	All	0.567	0.662	.011	21	view →
THYM	OS	Median	All	1.000	0.739	.001	18	view →
CHOL	OS	Tertile	All	0.320	0.876	.008	18	view →
BRCA	OS	Median	IV	0.525	0.177	.024	15	view →
ESCA	OS	Median	IV	0.698	0.222	.006	12	view →
UVM	DFS	Median	All	0.463	0.861	.006	12	view →
UCEC	DFS	Median	All	0.577	0.713	.008	12	view →
SCLC	OS	Quartile	II,III,IV	0.875	0.437	.010	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

MTA3–LIHC (OS)

Open the LIHC breakdown →